As expected, both signatures were more enriched in the 7/8 metastatic tumors with ESR1 mutation with WT TP53 (PT#1 and PT#2), recapitulating the ER signaling enhancement conferred by ESR1 mutations during metastatic development (Fig. 5a). This evidence concerns the gene ESR1 and metastatic neoplasm.